Captrust Financial Advisors Sells 8,909 Shares of BioNTech SE (NASDAQ:BNTX)

Captrust Financial Advisors cut its position in BioNTech SE (NASDAQ:BNTX) by 70.8% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,678 shares of the company’s stock after selling 8,909 shares during the quarter. Captrust Financial Advisors’ holdings in BioNTech were worth $437,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. Capstone Investment Advisors LLC purchased a new position in BioNTech in the third quarter worth $777,000. Bridgewater Associates LP purchased a new stake in shares of BioNTech during the third quarter worth about $674,000. Freedom Investment Management Inc. acquired a new position in shares of BioNTech during the third quarter valued at about $243,000. FMR LLC raised its position in shares of BioNTech by 797.8% in the 3rd quarter. FMR LLC now owns 6,299,929 shares of the company’s stock valued at $748,243,000 after purchasing an additional 5,598,190 shares during the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new stake in BioNTech in the 3rd quarter worth approximately $2,486,000. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Stock Performance

Shares of NASDAQ:BNTX opened at $120.69 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. BioNTech SE has a 1 year low of $76.53 and a 1 year high of $131.49. The firm has a market capitalization of $28.93 billion, a PE ratio of -57.47 and a beta of 0.22. The business’s 50 day moving average price is $113.91 and its 200-day moving average price is $100.17.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. During the same period in the previous year, the business posted $0.73 earnings per share. BioNTech’s quarterly revenue was up 38.9% on a year-over-year basis. As a group, equities research analysts expect that BioNTech SE will post -3.72 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $150.00 price objective on shares of BioNTech in a research note on Monday, November 18th. Wells Fargo & Company assumed coverage on BioNTech in a research report on Wednesday. They set an “overweight” rating and a $170.00 price target for the company. The Goldman Sachs Group raised BioNTech from a “neutral” rating to a “buy” rating and increased their price objective for the company from $90.00 to $137.00 in a report on Friday, November 8th. UBS Group upped their target price on BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a research report on Wednesday, September 18th. Finally, TD Cowen decreased their price objective on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a research note on Tuesday, November 5th. Four research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $140.76.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.